• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

An Introduction to Idiopathic Pulmonary Fibrosis

News
Slideshow

What are the early warning signs and symptoms of IPF? Click through this concise overview of the disease and its differential diagnosis.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma

FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma

Sydney Jennings
September 18th 2025
Article

The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

ACOG Publishes Revised Guidance on Maternal Immunization for COVID-19, Influenza, and RSV

ACOG Publishes Revised Guidance on Maternal Immunization for COVID-19, Influenza, and RSV

Grace Halsey
August 25th 2025
Article

ACOG CEO: “In the face of misinformation and vaccine hesitancy, a strong, evidence-based recommendation...from a trusted clinician can go a long way."

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis

FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis

Sydney Jennings
August 14th 2025
Article

The US FDA approved brensocatib as the first treatment for non–cystic fibrosis bronchiectasis.

Digital Asthma Program Improves Symptom Control in Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Digital Asthma Program Improves Symptom Control in Adults: Daily Dose

Sydney Jennings
August 6th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.